The Valley Desk

ArticleOncology and therapyPublished

Cost-effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer in England

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Bristol Myers Squibb. Affiliation source

Publication record

Type
Article
Venue
Oncology and therapy
Published
Subject terms
Cost-effectiveness; Neoadjuvant; Nivolumab; Non-metastatic Nsclc; Hta Submission
PubMed ID
41241660
PubMed Central ID
PMC12992869
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal